Drug news
FDA agrees to new labelling of Zevalin (Spectrum Pharma) to remove bioscan Indium 111
The FDA has agreed that Spectrum Pharma can remove from the labelling of Zevalin (ibritumomab tiuxetan) a requirement for a certain type of bioscan, known as an Indium-111 pretreatment imaging evaluation.Patients undergoing treatment with Zevalin no longer need to be exposed to unnecessary radiation with Indium-111. Zevalin is approved in the USA and EU for Follicular Non Hodgkins Lymphoma. Marketing of the drug in the USA is now by Spectrum Pharma which acquired the rights from a joint venture with Cell Therapeutics some time ago.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins